Celgene (CELG) Tops Q3 EPS by 10c; Boosts FY16 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celgene Reports Third Quarter 2016 Operating and Financial Results
October 27, 2016 7:34 AM EDT- Net Product Sales $2.97B in Q3:16; Increased 28% Y/Y
- 2016 Guidance and 2017 Targets Updated
- Over 150 Abstracts Expected at Medical Congresses in Q4
- FDA Grants Priority Review for REVLIMID® as Maintenance Treatment Post-Autologous Stem-Cell Transplant in Multiple Myeloma
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $2,969 million for the third quarter of 2016, a 28 percent increase from the same period in 2015. Net product sales growth includes a 1 percent negative impact from... More
